The latest interim analyses of the INSPIRE trial are very encouraging,” said Dr.Warnecke. “We are hopeful the final results of the trial will confirm important advantages of warm perfusion and ventilation using OCS™."
San Diego, CA (PRWEB) April 12, 2014
Today the latest results and research progress of the prospective INSPIRE trial, initiated in late 2011, will be announced at the International Society for Heart and Lung Transplantation’s 34th Annual Meeting and Scientific Sessions. The presentation will be given by Dr. Gregor Warnecke, Director of Thoracic Transplantation Program; Division of Cardiac, Thoracic, Transplantation and Vascular Surgery at Hanover Medical School, Germany.
INSPIRE is a randomized and controlled FDA trial that compares the preservation of regular donor lungs using the Organ Care System (OCS™), a device capable of transporting donor lungs in a perfused and ventilated warm state, to the standard-of-care cold static storage. The most recent interim analysis involving 245 study subjects shows a significant reduction in early lung allograft dysfunction, a multifactorial injury to the transplanted lung that develops within the first 72 hours of transplant.
“The latest interim analyses of the INSPIRE trial are very encouraging,” said Dr. Warnecke. “We are hopeful the final results of the trial will confirm important advantages of warm perfusion and ventilation using OCS™.”
INSPIRE is the largest prospective randomized trial in lung preservation to date and is expected to be fully enrolled in mid-2014 with a total 320 lung transplant recipients randomized.
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit professional organization with more than 2,700 members from over 45 countries dedicated to improving the core of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy. For more information, visit http://www.ishlt.org.